BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 22014541)

  • 1. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
    Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
    J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
    Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
    Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM
    Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent etanercept therapy in pediatric patients with psoriasis.
    Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G
    J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term etanercept in pediatric patients with plaque psoriasis.
    Paller AS; Siegfried EC; Eichenfield LF; Pariser D; Langley RG; Creamer K; Kricorian G
    J Am Acad Dermatol; 2010 Nov; 63(5):762-8. PubMed ID: 20605256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
    J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
    Gordon KB; Gottlieb AB; Leonardi CL; Elewski BE; Wang A; Jahreis A; Zitnik R
    J Dermatolog Treat; 2006; 17(1):9-17. PubMed ID: 16467018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
    N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis.
    Nestorov I; Zitnik R; DeVries T; Nakanishi AM; Wang A; Banfield C
    Br J Clin Pharmacol; 2006 Oct; 62(4):435-45. PubMed ID: 16995864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.
    Leonardi C; Strober B; Gottlieb AB; Elewski BE; Ortonne JP; van de Kerkhof P; Chiou CF; Dunn M; Jahreis A
    J Drugs Dermatol; 2010 Aug; 9(8):928-37. PubMed ID: 20684143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
    Krueger GG; Elewski B; Papp K; Wang A; Zitnik R; Jahreis A
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept.
    Tyring S; Bagel J; Lynde C; Klekotka P; Thompson EH; Gandra SR; Shi Y; Kricorian G
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):125-8. PubMed ID: 22188302
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
    BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.